Research & Development
Our R&D Department is involved in various activities, including formulation of new, stable and bioequivalent products and the improvement of the already marketed ones.
Our R&D Department is involved in various activities, including formulation of new, stable and bioequivalent products and the improvement of the already marketed ones. It ensures the development of robust formulations, preparation processes, data interpretation and transfer of technology via process validation.
Our R&D introduces 2-3 projects of innovative characteristics concerning altering both chemical and physical characterization of the drug moieties.
In specific, our latest developments include:
- Multiparticulate dosage forms
- omeprazole pellets of various strengths of mg/cap
- Semisolid dosage forms
- Diosmin cream 2%
- Diclofenac 3% in 2,5 % Hyaluronic acid, gel formulation
- Oral liquids with taste-masked solutions
- Deferiprone 100mg/ml
- Paracetamol 200mg/ml
- Furesomide of various strengths
- Solid dosage forms taste-masked via microencapsulation for APIs with unpleasant taste such as Glucosamine
- Calcium Carbonate Chewable 500mg/tab
- Sterile injectables
- Iron Sucrose 20mg/ml
- Iron Dextrane injectable
These activities are well supported in our new state of the art laboratory units, in our plant, resulting in the upscale of the manufacturing capacity.
